Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities (2016 - 2025)

Viking Therapeutics' Total Current Liabilities history spans 12 years, with the latest figure at $76.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 179.67% year-over-year to $76.7 million; the TTM value through Dec 2025 reached $76.7 million, up 179.67%, while the annual FY2025 figure was $76.7 million, 179.67% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $76.7 million at Viking Therapeutics, up from $26.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $76.7 million in Q4 2025 and bottomed at $8.8 million in Q4 2021.
  • The 5-year median for Total Current Liabilities is $17.4 million (2023), against an average of $21.7 million.
  • The largest YoY upside for Total Current Liabilities was 179.67% in 2025 against a maximum downside of 40.28% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $8.8 million in 2021, then soared by 150.02% to $21.9 million in 2022, then dropped by 12.81% to $19.1 million in 2023, then surged by 43.26% to $27.4 million in 2024, then soared by 179.67% to $76.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Total Current Liabilities are $76.7 million (Q4 2025), $26.1 million (Q3 2025), and $32.0 million (Q2 2025).